This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dolan Out at Bristol-Myers

Bristol-Myers added that its outside counsel, which is investigating the Plavix negotiations, "also confirmed that there is no evidence from which to conclude that the company or any of its employees acted unlawfully."

The company said Lacey's review was separate from a criminal investigation that the Justice Department' antitrust division launched into the Apotex arrangement. Lacey might make additional recommendations regarding "governance matters" when he issues his final report on the probe, Bristol-Myers said.

Because of the problems Bristol-Myers has had to deal with, its dividend has at times been thought to be in jeopardy, but for now at least it appears to be safe. Bristol-Myers declared a quarterly dividend of 28 cents a share and said it expects to pay the same rate in 2007, subject to the normal quarterly review by the board.

At the same time, the projected payout also assumes a favorable outcome to the Plavix litigation and an absence of sustained competition for the blood thinner next year.

Dolan, 50, is the third Big Pharma CEO in 17 months to leave his post earlier than had been planned.

Raymond Gilmartin left Merck (MRK) in May 2005, about 10 months ahead of his planned departure at the mandatory retirement age of 65. Gilmartin was replaced by long-time Merck executive Richard Clark .

Gilmartin paid the price for his company's sinking stock price and the mushrooming lawsuits stemming from Vioxx, the arthritis drug that Merck removed from the market in September 2004 for safety concerns.

4 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs